iron sucrose complex / Generic mfg. - LARVOL DELTA

Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Western Galilee Hospital-Nahariya | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2025 ➔ Dec 2027 | Trial primary completion date: Sep 2025 ➔ Sep 2027

Enrollment open • Trial completion date • Trial primary completion date • Anemia • Hematological Disorders

When Iron Bites Back: Severe Thrombocytopenia After Intravenous Iron Sucrose Therapy (Venofer). (PubMed, Cureus) - "Naranjo scoring suggested a probable drug-induced reaction. This case highlights a rare but important adverse effect of intravenous iron therapy and underscores the need for close hematologic monitoring."

Journal • Hematological Disorders • Immunology • Infectious Disease • Oncology • Thrombocytopenia

Iron-RANC: Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Fox Chase Cancer Center | Trial completion date: Feb 2027 ➔ Feb 2028 | Trial primary completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • Anemia • Hematological Disorders

Pump Iron: A Quality Improvement Project to Standardize Iv Iron Therapy and Reduce Adverse Reactions (ASPHO 2026) - "This modified administration bundle included a normal saline pre-bolus, famotidine premedication, longer infusion time (120 min) with two lines of concurrent normal saline, and standardized rescue medication response to reaction symptoms. Our institution's implementation of a standardized iron sucrose infusion protocol significantly reduced infusion reaction rates. Aligning administration practices with evidence-based strategies improved patient safety, patient/staff satisfaction, and our confidence in managing adverse events. This success highlights the value of interdisciplinary collaboration and structured process redesign."

Hematological Disorders • Immunology

IRONEASE: Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (clinicaltrials.gov) - P=N/A | N=128 | Completed | Sponsor: Sindh Institute of Urology and Transplantation | Recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ Nov 2025

Trial completion • Trial completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects (clinicaltrials.gov) - P3 | N=75 | Recruiting | Sponsor: AMAG Pharmaceuticals, Inc. | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Anemia • Hematological Disorders • Pediatrics

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) (clinicaltrials.gov) - P3 | N=129 | Recruiting | Sponsor: AMAG Pharmaceuticals, Inc. | Trial completion date: Aug 2024 ➔ Aug 2026 | Trial primary completion date: Aug 2024 ➔ Aug 2026

Trial completion date • Trial primary completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Pediatrics • Renal Disease

Anticoagulation dilemma in a patient with nephrotic syndrome and bleeding of unknown origin: A case-based approach to risk-benefit decision-making (ASH 2025) - "She received four units of packed red blood cells, one dose of Venofer 200 mg, and was started on pantoprazole 40 mg IV twice daily... This case highlights the complexities of anticoagulation management in patients with nephrotic syndrome. Despite the indication for anticoagulation, the absence of a documented thrombotic event, stabilization of hemoglobin following Apixaban cessation, and a moderate bleeding risk favored cessation of therapy. Multidisciplinary input and shared decision-making were essential in aligning the treatment plan with the patient's evolving clinical status and preferences."

Benefit-risk assessment • Clinical • Cardiovascular • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Hematological Disorders • Immunology • Inflammation • Nephrology • Peripheral Arterial Disease • Renal Disease • Thrombosis

Iron-deficiency anemia in premenopausal women: A comparative study of menstrual blood loss and malabsorptive etiologies (ASH 2025) - "These findings highlight the importance of heightened clinical vigilance and routine screening for malabsorption syndromes in patients presenting with unexplained mild to moderate anemia. Further research is warranted to investigate the mechanisms driving this pattern and to evaluate the impact of early diagnosis and targeted treatment on long-term outcomes."

Clinical • Anemia • Celiac Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease

Sulfide silver autometallography to differentiate the ultrastructural localization of iron-carbohydrate complexes inside macrophages. (PubMed, Sci Rep) - "Intravenous (IV) iron drugs, including iron-carbohydrate complexes such as iron sucrose (IS) and ferric carboxymaltose (FCM), are commonly used in the treatment of IDA...Interestingly, for both iron-carbohydrate complexes, the silver precipitates were observed exclusively inside the cells and not on the cell surface as seen for ferric ion. These results suggest that IS and FCM are not internalized by macrophages as ferric iron bound to transferrin and provide new insights into the cellular processing of iron-carbohydrate complexes to advance the understanding of iron homeostasis."

Journal • Hematological Disorders

Iron Deficiency Anemia: The Impact of Intravenous Iron Replacement Treatment on Health Care Costs (ASH 2023) - "Cohorts were classified based on index date treatment: FCM patients received ferric carboxymaltose; low-dose IV iron patients were treated with iron sucrose, iron dextran, or sodium ferric gluconate complex in sucrose. Despite the higher drug acquisition cost of FCM relative to low-dose IV iron, the drug price differential was offset by lower inpatient cost incurred in the FCM group. This resulted in similar all-cause total health care costs between FCM and low-dose IV iron in cancer and heart failure patients and lower total cost for FCM compared to low-dose IV iron in CKD patients. These results were more pronounced when comparing FCM with iron sucrose; the FCM group consistently had statistically lower total costs than iron sucrose in patients with cancer, HF and CKD."

HEOR • Anemia • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hematological Disorders • Nephrology • Renal Disease

New Insights into the Mechanism of Action of IV Iron Products: Kinetics of Macrophage Uptake and Their Intracellular Metabolic Fate (KIDNEY WEEK 2025) - "Methods Prior to initiating systematic studies of the response of macrophages, a comprehensive physicochemical characterization of two iron-carbohydrate complexes with different carbohydrate moieties: iron sucrose (IS), and ferric carboxymaltose (FCM) was performed...It was observed that IS undergoes rapid cellular uptake and nanoparticle degradation compared to FCM which is markedly slower and controlled. The results of these detailed in vitro studies provide unprecedented insight into the metabolic fate of IV iron products that advances understanding of their pharmacokinetic and pharmacodynamic profiles in vivo ."

Anemia • Hematological Disorders

Intravenously administered iron oxide nanoparticles with different coatings reversibly perturb immune cells in peripheral blood without inducing toxicity in mice. (PubMed, Front Toxicol) - "Biodistribution analysis demonstrated that the nanoparticle coating dictated their accumulation across various organs, with significant tumor accumulation observed for pegylated iron oxide nanoparticles and Venofer®. Iron oxide nanoparticle formulations exert a transient effect on the host immune system and some exhibit tumor accumulation, suggesting their potential for further development in cancer imaging and treatment."

Journal • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Understanding the kinetics of macrophage uptake and the metabolic fate of iron-carbohydrate complexes used for iron deficiency anemia treatment. (PubMed, J Control Release) - "Here, we thus performed a comprehensive dynamic characterization of two structurally distinct ICCs - iron sucrose (IS) and ferric carboxymaltose (FCM) - in primary human macrophages, key cells to the iron metabolism...Conversely, FCM is sequestered in enlarged endosomes for an extended time before its biodegradation, a phenomenon we term the Hamster Effect, which leads to slower, more sustainable iron release. These results provide unprecedented insights into the metabolic fate of ICCs, enhancing our understanding of their different pharmacokinetic and pharmacodynamic profiles in vivo."

Journal • Anemia • Hematological Disorders

IRONEASE: Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (clinicaltrials.gov) - P=N/A | N=128 | Recruiting | Sponsor: Sindh Institute of Urology and Transplantation | Not yet recruiting ➔ Recruiting

Enrollment open • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Hypophosphatemia Following Intravenous Iron in Chronic Kidney Disease (ERA 2025) - "Among available formulations, ferric carboxymaltose (FC) has been shown to induce a more profound and sustained decrease in serum phosphate compared to other formulations such as ferric derisomaltose and iron sucrose...The available intravenous iron formulations were Ferinject 50 mg/mL (FC) and Venofer 20 mg/mL (IS)...This effect is more pronounced until stage 3 and with higher cumulative iron doses, independently of baseline vitamin D and calcium levels. Given its potential clinical implications, routine phosphate monitoring should be considered, especially in patients receiving prolonged or high-dose IVIT."

Anemia • Chronic Kidney Disease • Hematological Disorders • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • FGF23

Impact of Intravenous Iron Replacement Therapy on Healthcare Costs for Patients with Iron Deficiency Anemia in the USA: A Retrospective Analysis. (PubMed, Drugs Real World Outcomes) - "Despite the typically higher drug acquisition cost of FCM versus low-dose intravenous iron, the price differential was offset by the lower inpatient cost incurred in the FCM cohort in each patient population. These findings suggest the potential economic benefit of FCM to reduce inpatient utilization and associated costs to patients and health plans compared with low-dose intravenous iron."

HEOR • Journal • Retrospective data • Anemia • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hematological Disorders • Nephrology • Oncology • Renal Disease

Efficacy of Ferric Carboxymaltose Versus Iron Sucrose in Non-dialysis Dependent Chronic Kidney Disease Patients (clinicaltrials.gov) - P=N/A | N=128 | Not yet recruiting | Sponsor: Sindh Institute of Urology and Transplantation

New trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

A Rare Case of Pulmonary and Gastric Malt Lymphoma in a Patient Presenting With Recurrent Microcytic Anemia (ATS 2025) - "The patient was started on combined Bendamustine and Rituximab therapy...Prophylactic was initiated with Bactrim and Acyclovir...Treatment options vary based on disease extent; radiation may be effective for localized MALT lymphoma, while immunochemotherapy is preferred for widespread disease. In this case, combined immunochemotherapy was initiated given the presence of both gastric and pulmonary involvement."

Clinical • Anemia • B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Oncology • Pain • MALT1

Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: American Regent, Inc. | Phase classification: P4 ➔ P2

Phase classification • Anemia • Hematological Disorders

Bioequivalence Study of Iron Sucrose Injection in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Not yet recruiting ➔ Completed

Trial completion

IV iron supplementation, dosage, and timing in pregnancy: A single-institution review on a maternal transfusion reduction bundle. (PubMed, Eur J Obstet Gynecol Reprod Biol) - "Substantial benefit is seen when IVFe is given in the early third trimester, especially with ≥6 weeks of latency and doses ≥800 mg."

Journal • Hematological Disorders • Obstetrics

Iron-RANC: Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy (clinicaltrials.gov) - P2 | N=34 | Recruiting | Sponsor: Fox Chase Cancer Center | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Feb 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Anemia • Hematological Disorders

A cost-effective innovation in anaemia management for paediatric haemodialysis-dependant chronic kidney disease patients (IPNA 2025) - "Following Ferinject® infusion, we observed significant increases in laboratory parameters including haemoglobin level, transferrin saturation and reticulocyte haemoglobin content and levels were maintained at 3-months post-infusion (Figure 1a). Ferinject® demonstrated comparable efficacy to Venofer® in maintaining laboratory parameters (Figure 1b). Strikingly, Ferinject® treatment was associated with significantly decreased number of infusions per month (~ 10-fold) and a significant cost-saving (~ 5-fold) (Figure 1c)."

Clinical • Cost effectiveness • HEOR • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Pediatrics • Renal Disease

Bioequivalence Study of Iron Sucrose Injection in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

New P1 trial